| Multiple Sclerosis, Secondary Progressive
Briumvi vs Kesimpta
Side-by-side clinical, coverage, and cost comparison for multiple sclerosis, secondary progressive.Deep comparison between: Briumvi vs Kesimpta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsKesimpta has a higher rate of injection site reactions vs Briumvi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Kesimpta but not Briumvi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Briumvi
Kesimpta
At A Glance
IV infusion
Every 24 weeks
Anti-CD20 monoclonal antibody
SC injection
Once monthly
Anti-CD20 monoclonal antibody
Indications
- Multiple Sclerosis, Relapsing-Remitting
- Clinically isolated syndrome
- Multiple Sclerosis, Secondary Progressive
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
- Clinically isolated syndrome
Dosing
Multiple Sclerosis, Relapsing-Remitting; Clinically isolated syndrome; Multiple Sclerosis, Secondary Progressive 150 mg IV infusion (first infusion), followed by 450 mg IV infusion 2 weeks later, then 450 mg IV every 24 weeks; pre-medicate with methylprednisolone (or equivalent corticosteroid) and antihistamine before each infusion.
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Clinically isolated syndrome 20 mg SC injection at Weeks 0, 1, and 2 (loading doses), then 20 mg SC once monthly starting at Week 4.
Contraindications
- Active HBV infection
- History of life-threatening infusion reaction to ublituximab-xiiy
- Active HBV infection
- History of hypersensitivity to ofatumumab or life-threatening injection-related reaction to KESIMPTA, including anaphylaxis and angioedema
Adverse Reactions
Most common (>=10%) Infusion reactions, upper respiratory tract infections
Serious Infusion reactions, infections, reduction in immunoglobulins, liver injury
Postmarketing Liver injury, progressive multifocal leukoencephalopathy
Most common (>10%) upper respiratory tract infections, injection-related reactions (systemic), headache, injection-site reactions (local)
Serious infections, injection-related reactions and hypersensitivity reactions, reduction in immunoglobulins, liver injury
Postmarketing hypersensitivity reactions, liver injury
Pharmacology
Anti-CD20 chimeric monoclonal IgG1 antibody with reduced fucose content; binds CD20 on pre-B and mature B lymphocytes and causes cell lysis via antibody-dependent cellular cytolysis and complement-dependent cytolysis.
Ofatumumab is a recombinant human IgG1 monoclonal antibody that binds CD20 on pre-B and mature B lymphocytes, resulting in antibody-dependent cellular cytolysis and complement-mediated lysis; the precise mechanism in multiple sclerosis is unknown but is presumed to involve B-lymphocyte depletion.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Briumvi
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Kesimpta
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Briumvi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Kesimpta
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Briumvi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Kesimpta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BriumviView full Briumvi profile
KesimptaView full Kesimpta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.